Vivos Therapeutics, Inc. (VVOS)
$
5.17
+0.74 (14.31%)
Key metrics
Financial statements
Free cash flow per share
-1.6271
Market cap
26.1 Million
Price to sales ratio
1.7836
Debt to equity
0.3174
Current ratio
0.7673
Income quality
1.2432
Average inventory
0
ROE
-1.7043
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Vivos Therapeutics, Inc. is a medical technology company that focuses on developing and commercializing innovative treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. The fiscal year 2024 financial data reflects a net total of other income and expenses of $35,000.00 which encompasses non-core financial activities. The company's operational profitability is denoted by an operating income ratio of -0.74 highlighting its ability to generate earnings from its core business activities. Shareholders can gauge profitability on an individual basis, as indicated by the earnings per share (EPS) of -$1.68. Furthermore, the company incurred an income tax expense of $0.00 demonstrating its tax obligations as part of its business operations. Based in Highlands Ranch, Colorado, and founded in 2016, Vivos Therapeutics offers the Vivos System, a non-invasive, non-surgical, and non-pharmaceutical multi-disciplinary treatment modality aimed at providing solutions for dentofacial abnormalities, OSA, and snoring. Additionally, the company provides the VivoScore Program, which includes screening and home sleep testing for both adults and children, and primarily markets its offerings to licensed professionals, with a focus on general dentists in the United States and Canada. The company operates within the Healthcare sector, where it is recognized as a key player in the Medical - Devices industry, making significant contributions to the overall market landscape. Currently, the stock is affordable at $5.17 making it an appealing option for budget-conscious investors. However, it should be noted that the stock has a low average trading volume of 673,753.00 indicating lower market activity. With a market capitalization of $30,448,818.00 Vivos Therapeutics is classified as a small-cap player, reflecting its position within the industry. The company's commitment to driving innovation and growth showcases its potential impact on the sector, as it continues to address critical healthcare needs through its advanced treatment solutions.
Is Vivos Therapeutics, Inc. (VVOS) a good investment?
Investing in Vivos Therapeutics, Inc. (VVOS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Vivos Therapeutics, Inc. (VVOS)'s stock forecast?
Analysts predict Vivos Therapeutics, Inc. stock to fluctuate between $1.97 (low) and $6.28 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Vivos Therapeutics, Inc.'s market capitalization?
As of 2025-07-07, Vivos Therapeutics, Inc.'s market cap is $30,448,818, based on 5,889,520 outstanding shares.
How does Vivos Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Vivos Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Vivos Therapeutics, Inc. (VVOS) stock?
To buy Vivos Therapeutics, Inc. (VVOS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for VVOS. Place an order (Market, Limit, etc.).
What is the best time to invest in Vivos Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Vivos Therapeutics, Inc. stock ever split?
Vivos Therapeutics, Inc.'s last stock split was 1:25 on 2023-10-27.
How did Vivos Therapeutics, Inc. perform in the last earnings report?
Revenue: $15,031,000 | EPS: -$1.68 | Growth: -84.92%.
Where can I find Vivos Therapeutics, Inc.'s investor relations reports?
Visit https://vivos.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Vivos Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Vivos Therapeutics, Inc. stock?
All-time high: $271.49 (2021-04-12) | All-time low: $1.91 (2024-05-30).
What are the key trends affecting Vivos Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
13 days ago
LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive results for the treatment of OSA in children using Vivos' patented Daytime-Nighttime Appliance (DNA).
seekingalpha.com
2 months ago
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Brad Amman - CFO Kirk Huntsman - Chairman and CEO Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2025 Earnings Call.
zacks.com
2 months ago
Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.63 per share a year ago.
globenewswire.com
2 months ago
LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025.
zacks.com
2 months ago
Vivos Therapeutics (VVOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com
3 months ago
By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced a definitive agreement to acquire the operating assets of The Sleep Center of Nevada (“SCN”), the largest operator of medical sleep centers in Nevada.
seekingalpha.com
3 months ago
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Bradford Amman - CFO, Treasurer & Secretary Kirk Huntsman - Co-Founder, Chairman & CEO Conference Call Participants Guyn Kim - Water Tower Research Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics Full Year 2024 Earnings Conference Call. [Operator Instructions] This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days.
zacks.com
3 months ago
Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $3.05 per share a year ago.
globenewswire.com
3 months ago
Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults) and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the full year ended December 31, 2024.
globenewswire.com
3 months ago
LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025.
See all news
